
AstraZeneca president to lead Sanofi UK
pharmafile | October 9, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Sanofi, Tarja Stenvall
Sanofi has appointed Tarja Stenvall to be its new general manager for the UK and Ireland.
Stenvall joins Sanofi from AstraZeneca where she was country president for AstraZeneca Belgium and Luxembourg.
In her new role she will lead the UK and Ireland offices in supporting the treatment needs of patients through its portfolio of medicines, vaccines and therapeutic solutions.
David Loew who is the firm’s senior VP of commercial operations in Europe says: “We are excited to bring Tarja on board as a new member of the European leadership team. Her broad experience in diverse markets will ensure she can lead our UK and Ireland affiliates to provide a solid contribution to patients’ needs in those two markets.”
Stenvall holds a degree in Economics from the Helsinki School of Economics and Business Administration in Helsinki in Finland, and an MBA from the University of South Carolina (US).
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …






